Correlation of Serum Interleukin-2 Levels, Soluble Interleukin-2 Receptors and T Lymphocyte Subsets in Cancer Patients
Correlation of Serum Interleukin-2 Levels, Soluble Interleukin-2 Receptors and T Lymphocyte Subsets in Cancer Patients
复制标题
癌症患者血清白细胞介素2水平、可溶性白细胞介素2受体与T淋巴细胞亚群的相关性
作者：
P. Lissoni;S. Barni;F. Rovelli;R. Rescaldani;V. Rizzo;A. Biondi;G. Tancini
在大多数转移性癌症患者中已经观察到白细胞介素-2（IL-2）的体外产生减少。然而，由于以前的生物学和酶免疫测定方法的灵敏度太低，目前还没有关于体内血液IL-2水平的数据。最近发展的一种灵敏的RIA方法使我们能够开始在基础条件下在人类实体瘤中IL-2产生的初步调查。该研究包括42名癌症患者。乳腺癌和肺癌是最常见的两种肿瘤。检测患者血清IL-2、可溶性IL-2受体（SIL-2 R）水平及CD_4/CD_8比值。对照组为58例健康志愿者。转移患者（n = 23）的平均血清IL-2水平显著低于无转移患者（n = 19）。CD 4/CD 8比值低者（n = 16）IL-2均值明显低于CD 4/CD 8比值正常者（n=26）。最后，SIL-2 R水平升高的患者的平均IL-2浓度显著低于正常值的患者。这些结果表明，转移性播散与体内IL-2产生减少有关，并且IL-2产生减少在低CD 4/CD 8比率的患者中更常见。
An interleukin-2 (IL-2) in vitro reduced production has been observed in most metastatic cancer patients. At present, however, there are no data on blood IL-2 levels in vivo, because of the too low sensitivity of previous biological and enzyme immunoassay methods. The recent development of a sensitive RIA method allowed us to start a preliminary investigation of IL-2 production in basal conditions in human solid tumors. The study included 42 cancer patients. Breast and lung cancer were the two commonest neoplasms. Serum levels of IL-2 and soluble IL-2 receptors (SIL-2R), and CD4/CD8 ratio were measured in each patient. The control group consisted of 58 healthy subjects. Mean serum levels of IL-2 were significantly lower in metastatic patients (n = 23) than in those without metastases (n = 19). Patients with low CD4/CD8 ratio (n = 16) had significantly lower mean values of IL-2 than those with normal ratio (n=26). Finally, mean IL-2 concentrations were significanty lower in patients with elevated levels of SIL-2R than in those with normal values. These results would suggest that metastatic dissemination is associated with a decreased IL-2 production in vivo, and that reduced IL-2 production is more frequent in patients with low CD4/CD8 ratio.
I 期试验中重组白细胞介素 2 的毒性、药代动力学和免疫调节作用。
影响因子：
11.2
作者：
Thompson,JA;Lee,DJ;Cox,WW;Lindgren,CG;Collins,C;Neraas,KA;Dennin,RA;Fefer,A
通讯作者：
Fefer,A